Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma — Stella

Home/T-cell Lymphoma/

View on ClinicalTrials.gov

Recruiting

Back to T-cell Lymphoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Key details

Phase

Safety & dosing

Sponsor

Jonathan Brammer

Collaborators

Incyte Corporation

Enrollment target

~44 participants

Started

February 2026

Primary completion

December 2026

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.